Neuroblastoma Case Study:

Achieving rapid access for paediatric patients with a deadly disease

Background

• A small pharma without a market access team in-licensed an immunotherapy only months prior to commercial launch
• Product was granted marketing authorization by CHMP under exceptional circumstances
• LatticePoint developed the pricing strategy for originator/R&D company and was asked by the acquiror to provide the market access support and execution

LatticePoint Engagement

• Develop launch sequencing to optimize list prices across the EU and minimize reference pricing impact on revenue
• Evaluate Early Access Program (EAP) opportunities for patient access and revenue generation, including application preparation
• Evaluate and develop Managed Entry Agreements (MEAs) for key markets based on evidence available
• Develop of reimbursement dossiers, including:
  • Synthesizing clinical trial data and data gaps to support HTA evaluations
  • Reinforcing evidence arguments via systematic literature reviews (SLRs), meta-analyses and indirect comparisons
  • Developing cost effectiveness and budget impact models (as relevant)

LatticePoint engaged HTAs and payers in-country with the respective affiliate leaders and achieved target pricing and reimbursement in all countries.